Regorafenib in metastatic colorectal cancer: An exploratory biomarker trial.

被引：0
|
作者：
Salem, Mohamed E.
Petricoin, Emanuel
Wellstein, Anton
Pierobon, Mariaelena
Wang, Hongkun
Mikhail, Sameh
Hartley, Marion L.
Smaglo, Brandon George
Lou, Emil
Alistar, Angela Tatiana
Dorsch-Vogel, Karen
Pishvaian, Michael J.
He, Aiwu Ruth
Kim, Alexander Y.
Shivapurkar, Narayan
Reddy, Sandeep K.
Marshall, John
机构：
[1] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] George Mason Univ, Manassas, VA USA
[3] Ohio State Univ, James Canc Hosp, Ctr Comprehens Canc, Solove Res Inst, Columbus, OH 43210 USA
[4] Univ Minnesota, Hopkins, MN USA
[5] Wake Forest Sch Med, Winston Salem, NC USA
[6] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[7] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med & Oncol, Washington, DC USA
[8] Georgetown Univ, Lombardi Comprehens Canc Ctr, Innovat Ctr Biomed Informat, Washington, DC USA
[9] Medstar Georgetown Univ Hosp, Intervent Radiol, Washington, DC USA
[10] Caris Life Sci, Phoenix, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps773
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS773
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Practical considerations in the use of regorafenib in metastatic colorectal cancer
    Loupakis, Fotios
    Antonuzzo, Lorenzo
    Bachet, Jean-Baptiste
    Kuan, Feng-Che
    Macarulla, Teresa
    Pietrantonio, Filippo
    Xu, Rui-Hua
    Taniguchi, Hiroya
    Winder, Thomas
    Yuki, Satoshi
    Zeng, Shan
    Bekaii-Saab, Tanios
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [32] Circulating miR-652-3p as a biomarker of resistance to regorafenib in metastatic colorectal cancer patients
    Hedayat, Somaieh
    Khan, Khurum
    Cunningham, David
    Vlachogiannis, George
    Lampis, Andrea
    Marchetti, Silvia
    Fassan, Matteo
    Begum, Ruwaida
    Schirripa, Marta
    Loupakis, Fotios Fotios
    Valeri, Nicola
    CANCER RESEARCH, 2019, 79 (13)
  • [33] Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial
    Xu, Jianming
    Xu, Rui-Hua
    Qin, Shukui
    Pan, Hongming
    Bai, Yuxian
    Chi, Yihebali
    Wang, Liwei
    Bi, Feng
    Cheng, Ying
    Liu, Tianshu
    Ma, Dong
    Shen, Lin
    Ba, Yi
    Liang, Jun
    Wang, Xin
    Yau, Thomas C. C.
    Ma, Brigette B.
    Yeh, Kun-Huei
    Lin, Jen-Kou
    Kappeler, Christian
    Shapiro, Jo Ann
    Kalmus, Joachim
    Li, Jin
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (08) : 1307 - 1316
  • [34] An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab
    Sclafani, Francesco
    Rimassa, Lorenza
    Colombo, Piergiuseppe
    Destro, Annarita
    Stinco, Sergio
    Lutman, Fabio R.
    Carnaghi, Carlo
    Beretta, Giordano
    Zanello, Alessandro
    Roncalli, Massimo
    Giordano, Laura
    Santoro, Armando
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2015, 30 (01): : E73 - E80
  • [35] EXPERIENCE WITH REGORAFENIB TREATMENT FOR METASTATIC COLORECTAL CANCER AT AICHI CANCER CENTER
    Uegaki, Shiori
    Ura, Takashi
    Tanigushi, Hiroya
    Kadowaki, Shigenori
    Takahari, Daisuke
    Andoh, Masashi
    Kato, Mina
    Tajika, Masahiro
    Muri, Kei
    ANNALS OF ONCOLOGY, 2014, 25
  • [36] Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic colorectal cancer treated with regorafenib
    Andersen, Iben R.
    Olesen, Rene
    Boysen, Anders K.
    Jensen, Lars H.
    Mortensen, Frank, V
    Nielsen, Dennis T.
    Rasmussen, Finn
    ACTA RADIOLOGICA, 2019, 60 (07) : 836 - 845
  • [37] Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer
    Ducreux, Michel
    Tabernero, Josep
    Grothey, Axel
    Arnold, Dirk
    O'Dwyer, Peter J.
    Gilberg, Frank
    Abbas, Alexander
    Das Thakur, Meghna
    Prizant, Hen
    Irahara, Natsumi
    Tahiri, Anila
    Schmoll, Hans -Joachim
    Van Cutsem, Eric
    de Gramont, Aimery
    EUROPEAN JOURNAL OF CANCER, 2023, 184 : 137 - 150
  • [38] TDM of Regorafenib in patients with metastatic colorectal cancer: preliminary results
    Beinse, G.
    Khoudour, N.
    Joly, C.
    Tournigand, C.
    Rousseau, B.
    Hulin, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 44 - 45
  • [39] Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
    Goldstein, Daniel A.
    Ahmad, Bilal B.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3727 - +
  • [40] Treatment options after regorafenib failure in metastatic colorectal cancer
    Berretta, M.
    Fiorica, F.
    Quagliariello, V.
    Laterza, M. M.
    Facchini, G.
    Montopoli, M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (13) : 4441 - 4442
12345